DaVita (NYSE:DVA – Get Free Report) had its target price hoisted by stock analysts at TD Cowen from $220.00 to $228.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen‘s price target indicates a potential upside of 25.77% from the company’s current price.
DVA has been the subject of several other reports. Oppenheimer set a $220.00 target price on DaVita in a research note on Friday, August 7th. Barclays upped their price target on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, October 9th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $265.00 price objective on shares of DaVita in a research note on Wednesday, August 5th. Finally, Raymond James Financial set a $220.00 price objective on shares of DaVita in a research note on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, DaVita currently has a consensus rating of “Moderate Buy” and an average target price of $237.00.
Check Out Our Latest Stock Report on DaVita
DaVita Trading Down 3.3%
NYSE DVA traded down $6.21 on Monday, hitting $181.29. 266,040 shares of the company were exchanged, compared to its average volume of 894,088. The company has a market cap of $11.40 billion, a PE ratio of 13.30, a PEG ratio of 0.48 and a beta of 0.87. DaVita has a 12 month low of $101.00 and a 12 month high of $247.49. The stock has a fifty day moving average of $181.36 and a 200-day moving average of $176.50.
DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $3.82 earnings per share for the quarter, beating the consensus estimate of $3.57 by $0.25. DaVita had a net margin of 6.49% and a negative return on equity of 225.93%. The firm had revenue of $3.58 billion during the quarter, compared to the consensus estimate of $3.52 billion. During the same period in the previous year, the firm posted $2.51 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. On average, analysts expect that DaVita will post 14.74 earnings per share for the current year.
Institutional Investors Weigh In On DaVita
Large investors have recently modified their holdings of the stock. Berkshire Hathaway Inc purchased a new stake in DaVita in the 2nd quarter worth about $6,425,269,000. BlackRock Inc. purchased a new stake in DaVita during the 2nd quarter worth about $547,520,000. Dimensional Fund Advisors LP lifted its holdings in DaVita by 5.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,145,436 shares of the company’s stock worth $176,037,000 after purchasing an additional 56,336 shares in the last quarter. Bank of America Corp DE bought a new position in DaVita in the 2nd quarter worth about $145,057,000. Finally, Bank of New York Mellon Corp grew its holdings in DaVita by 81.2% during the 1st quarter. Bank of New York Mellon Corp now owns 457,493 shares of the company’s stock valued at $70,312,000 after buying an additional 204,984 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.
About DaVita
DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.
DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.
The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.
See Also
- Five stocks we like better than DaVita
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
- 3 Waste Services Stocks With More Growth Than You Might Expect
- Alphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
